Indian Firms Look To Cash In On Growing Demand For Biosimilars
This article was originally published in The Pink Sheet Daily
Executive Summary
Dr. Reddy’s to introduce one new biosimilar a year, CEO vows.
You may also be interested in...
India’s Biocon Buys 70 Percent Stake In German Drug Firm AxiCorp GmbH
AxiCorp heralds Biocon’s European foray into biosimilars, firm’s owner Kiran Mazumdar says.
Ranbaxy Strengthens Ties With Injectables Specialist Zenotech
Expanded investment will help Ranbaxy’s position in the specialty sector, firm says; the two Indian companies have already collaborated on development of a biosimilar.
Indian Bayh-Dole Evokes Mixed Reactions
Is a 1980s technology transfer solution from the U.S. a good fit for India?